📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 3 — Stability Summary (OBX-319)
Why it exists. Chemistry, manufacturing, and controls evidence establishing product quality and consistency.
How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.
Format & governing standard. —
Document ID: M3-STAB
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q
Long-term storage at 2-8 C protected from light; a proposed shelf life supported by real-time, accelerated, and stress ICH Q5C/Q1A(R2) data, with defined in-use (room-temperature) and transport-excursion allowances.
OBX-319 is a humanized IgG1 anti-CD19 x anti-CD20 bispecific monoclonal antibody produced in Chinese hamster ovary (CHO) cell culture and purified through a Protein A capture step followed by orthogonal polishing chromatography. As a large, conformationally complex glycoprotein, its quality is a function of higher-order structure, correct heavy/light chain pairing across the two distinct binding arms, and the integrity of both antigen-binding functions; consequently, stability is established on the physicochemical and biological attributes that govern potency, purity, and safety rather than on any single degradant. The stability program therefore follows the biotechnological-product framework of ICH Q5C in conjunction with the general principles of Q1A(R2), the specification framework of Q6B, and the manufacturing/control expectations of Q11, and is designed to demonstrate that the drug substance (DS) and the drug product (DP) — a subcutaneous solution presented in a Type I glass prefilled syringe with a coated elastomeric stopper — remain within their release and shelf-life acceptance criteria across the labeled storage period and defined excursions. The program is supported at all relevant conditions by stability-indicating, appropriately qualified/validated analytical methods capable of resolving the size, charge, and functional degradation pathways characteristic of a bispecific IgG1.
No comments yet. Be the first to say something!
Stability is evaluated under long-term, accelerated, and (as applicable) stress conditions per ICH Q1A(R2)/Q5C on representative drug-substance and drug-product batches, using stability-indicating methods for the attributes in 3.2.S.4 / 3.2.P.5.
Storage conditions and study matrix. The primary stability protocol comprises at minimum three DS and three DP batches manufactured from qualified cell-culture and downstream processes at the intended commercial scale, placed on study under the conditions defined for a refrigerated biotechnological product:
Because degradation of a monoclonal antibody is molecule-specific and biologics are generally not amenable to reduction of testing, a full study design (rather than bracketing or matrixing) is applied; where bracketing/matrixing of presentations is proposed it is justified per Q1D.
Attributes and stability-indicating methods. Testing at each pull point covers the panel that governs OBX-319 quality and is capable of trending change over the storage period:
Photostability, freeze-thaw, in-use, and transport. A confirmatory photostability study is conducted per ICH Q1B to define the light-protection labeling reflected in the storage statement. DS freeze-thaw cycling supports frozen storage/handling of the substance. For the subcutaneous DP, an in-use / room-temperature hold study defines the permitted time the prefilled syringe may be kept at ambient conditions prior to administration, and a transport-simulation/excursion study (including thermal cycling and mechanical stress representative of the distribution chain) supports the defined temperature-excursion allowance. Endotoxin, sterility, and CCI are addressed within the sterile-product control strategy at the appropriate stability stations.
Analytical continuity and ongoing stability. Methods are the qualified/validated stability-indicating procedures described in 3.2.S.4 and 3.2.P.5; reference standards are qualified and bridged across batches so that potency and purity trends are comparable throughout the program. A post-approval stability commitment places the first commercial-scale batches, and at least one batch per year thereafter, on long-term study under a defined ongoing-stability protocol, with the annual product review assessing conformance to the shelf-life criteria.
The data support the proposed storage condition and shelf life in the type i glass prefilled syringe with a coated elastomeric stopper, with defined in-use and excursion allowances.
Real-time 2-8 C data, supported by accelerated and stress results and by the demonstrated stability-indicating capability of the size, charge, and functional methods, show that OBX-319 DS and DP remain within their 3.2.S.4 / 3.2.P.5 acceptance criteria across the claimed period, with any change in aggregation, fragmentation, charge variants, sub-visible particulates, and potency remaining within limits and statistically consistent with the assigned shelf life per ICH Q1E. The refrigerated, light-protected storage statement, the in-use room-temperature hold, and the transport-excursion allowance are each justified by the corresponding study arms, and the post-approval ongoing-stability commitment provides continued verification. These conclusions are specific to the bispecific IgG1 modality and its container-closure system and are consistent with the biotechnological-product stability expectations of ICH Q5C/Q6B.
Governing guidelines: ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q.